Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Cathinon-Derivate

α-PVP

C15H21NO CAS 14530-33-7 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bevorzugter Name
α-PVP
IUPAC-Name
1-phenyl-2-pyrrolidin-1-ylpentan-1-one
CAS-Nummer der Stammverbindung (Referenz)
14530-33-7
Summenformel
C15H21NO
Molekulargewicht
231.33 g/mol
InChIKey
YDIIDRWHPFMLGR-UHFFFAOYSA-N
PubChem
CID 11148955
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
alpha-PVP a-PVP aPVP alpha-pyrrolidinopentiophenone O-2387

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

alpha-PVP (alpha-Pyrrolidinovalerophenone / alpha-Pyrrolidinopentiophenone)

Potent Stimulant (Ultra-High-Affinity NDRI) Substituted cathinone / Pyrrolidinophenone (desmethylpyrovalerone)
Geprüfte PubChem- & CAS-Identität C15H21NO · CAS 14530-33-7 · CID 11148955
Kalibrierte Lieferform Reines Kristall / Analyse-Pulver (≥98 %)
≥98 % analytische Reinheit geprüft 231.34 g/mol
WHO-, PubMed- & PubChem-Quellen 4 cited records

Rezeptor-Telemetrie & Wirkmechanismus

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

One of the most potent dopamine-norepinephrine reuptake inhibitors (NDRIs) characterized in vitro: high lipophilicity from the pyrrolidine ring drives rapid blood-brain barrier permeation, yielding DAT IC50 = 12.8–19.7 nM (Ki = 22.2 nM) and NET IC50 = 14.2–46 nM (Ki = 122 nM) with zero substrate release and negligible SERT inhibition (IC50 > 10,000–57,000 nM; DAT/SERT ratio > 781–2,900). Neurochemical and cardiovascular actions reflect primarily the (S)-enantiomer.

Biotransformation & Active Metabolites

Metabolized by hepatic CYP2B6, CYP2D6, CYP2C19, and CYP3A4 primarily to 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-ol (OH-alpha-PVP) and 2''-oxo-alpha-PVP lactam. Human elimination half-life is ~2.1 hours, with clinical BP/HR peaking at 40 minutes.

Zeitliche Pharmakokinetik

Fierce, razor-sharp catecholaminergic rush marked by intense psychomotor stimulation, hyper-vigilance, compulsive repeated exposure cravings, strong peripheral vasoconstriction, and rapid escalation into agitation and paranoia.

  1. Onset 2–20 minutes oral
  2. Peak Window 1–2.5 hours (clinical cardiovascular peak at 40–60 minutes)
  3. Total Window 2–6 hours (clinical subjective duration 3–5 hours)
  4. Residual / Half-Life 4–12 hours of insomnia, adrenergic tension, anxiety, and crash; human elimination half-life is ~2.1 hours.

Extremely steep dose-response curve: threshold starts at 1 mg, common oral range is 10–25 mg, and exceeding 40–50 mg (or binge repeated exposure) carries a documented high rate of excited delirium, paranoid psychosis, hyperthermia (40–41 °C), rhabdomyolysis, acute renal failure, and cardiac arrest.

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
1 mg
Cognitive & Sensory

Subtle increase in alertness, vigilance, and wakefulness.

Somatic & Autonomic

Faint adrenergic crispness.

Light
5–10 mg
Cognitive & Sensory

Brisk mental energy, task focus, talkativeness, and modest mood lift.

Somatic & Autonomic

Noticeable elevation in heart rate and blood pressure, dry mouth, and appetite suppression.

Common Reference
10–25 mg
Cognitive & Sensory

Intense psychomotor rush, ego inflation, heightened libido, rapid thought acceleration, and strong urge to redose.

Somatic & Autonomic

Marked tachycardia, systolic/diastolic hypertension peaking around 40–60 minutes, sweating, jaw clenching, and vasoconstriction.

Strong
25–40 mg (CAHMA strong: 25–50 mg)
Cognitive & Sensory

Forced, jittery stimulation, restless tremors, hyper-vigilant anxiety, thought loops, and paranoid suspicion.

Somatic & Autonomic

Severe peripheral vasoconstriction, muscle spasms, restless legs, bruxism, chest tightness, and hyperthermia.

Heavy / Toxic Zone
40–50+ mg
Cognitive & Sensory

Acute paranoid psychosis, terrifying hallucinations, violent agitation, and excited delirium.

Somatic & Autonomic

Life-threatening hyperthermia (40–41 °C), rhabdomyolysis, acute kidney failure, myoclonus, seizures, cerebral hemorrhage, and myocardial infarction.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

12.8 nM DAT and 14.2 nM NET blockade combined with MAO inhibition causes immediate, fatal hypertensive crisis, stroke, and hyperpyrexia.

All other stimulants and 25x-NBOMe / 25x-NBOH (Cocaine, alpha-PHP, alpha-PiHP, MDPHP, NEP, Hexen, MDMA, Amphetamines)

Extreme synergistic tachycardia, vasospasm, hyperthermia, rhabdomyolysis, seizures, and cardiac arrest.

Tramadol and Opioids

Tramadol triggers convulsions; opioids risk fatal respiratory depression once alpha-PVP's ~2.1-hour half-life clears.

Hohes Risiko — Vermeiden

Alcohol and GHB/GBL

Worsens dehydration, hyperthermia, and rhabdomyolysis while masking lethal depressant intoxication.

Dissociatives (PCP/PCE analogues) and Psychedelics

High probability of triggering acute psychotic delirium, extreme panic, and uncontrolled behavioral crises.

Vorsicht / Abschwächung

CYP2D6 / CYP3A4 / CYP2C19 / CYP2B6 inhibitors

Slows hepatic oxidation of alpha-PVP, raising blood levels toward the >100 ug/L clinical intoxication and >300 ug/L overdose range.

Cannabis

Strongly provokes paranoid delusions and severe tachycardia.

Isomeren- & Strukturvergleich

alpha-PVP is the sharpest, most noradrenergically intense benchmark of the pyrovalerone family (NET IC50 14.2 nM vs. 41.4 nM for alpha-PiHP and 60–935 nM for MDPHP). Compared to 6-carbon homologue alpha-PHP, alpha-PVP has a slightly shorter total window (2–6 h vs. 2–8 h) and shorter after-effects (4–12 h vs. up to 48 h), while hitting with a harsher cold adrenergic edge. Compared to NEP and Hexen, alpha-PVP is ~2.4–10x more potent at DAT/NET.

Stabilität & Lagerung

Form: White or off-white odorless crystalline powder or crystals as the hydrochloride salt (mp ~161.3 °C; freebase mp ~173 °C). · HCl salt is soluble in ethanol (~20 mg/mL), PBS (pH 7.2, ~10 mg/mL), DMSO (~10 mg/mL), and DMF (~3 mg/mL).

Store dry and tightly sealed away from light and heat.

Cross-Tolerance & Dependence Profile

Very high addiction liability due to rapid blood-brain barrier entry and ~2.1-hour half-life. Cross-tolerant with alpha-PHP, alpha-PiHP, MDPHP, NEP, and cocaine (3–7 days to halve, 1–2 weeks to baseline).

Analytische & toxikologische Monographie

alpha-PVP (alpha-pyrrolidinovalerophenone / O-2387; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one; freebase CAS 14530-33-7, hydrochloride CAS 5485-65-4, PubChem CID 11148955) is the prototypical five-carbon pyrrolidinophenone cathinone queued in weekly synthesis slot #13 as pure analytical crystals or crystalline powder (C15H21NO, 231.34 g/mol). Its lipophilic pyrrolidine ring enables rapid blood-brain barrier permeation and ultra-potent, pure catecholamine uptake blockade (DAT IC50 = 12.8–19.7 nM, NET IC50 = 14.2–46 nM) with negligible serotonin transporter activity (SERT IC50 > 10,000 nM). Controlled human pharmacodynamic studies demonstrate acute increases in blood pressure and heart rate peaking at 40–60 minutes, with primary subjective effects resolving across 3–5 hours alongside an elimination half-life of ~2.1 hours via hepatic CYP2B6/2D6/2C19/3A4 metabolism. Because alpha-PVP has an exceptionally steep dose-response curve, volumetric liquid measurement or laboratory-grade milligram weighing is indispensable: oral threshold activity begins at 1 mg, light stimulation spans 5–10 mg, common stimulation sits at 10–25 mg, strong forced stimulation with vasoconstriction and hyper-vigilance occurs at 25–40 mg, and amounts above 40–50 mg (or binge repeated exposure) carry documented risks of paranoid psychosis, excited delirium, hyperthermia (40–41 °C), rhabdomyolysis, acute renal failure, cerebral hemorrhage, and myocardial infarction. Compared to alpha-PHP and alpha-PiHP, alpha-PVP delivers the strongest noradrenergic rush (NET IC50 14.2 nM) with a shorter residual tail than alpha-PHP, while exceeding NEP and Hexen in transporter potency several-fold. Never combine alpha-PVP with MAOIs, any other stimulant, tramadol, opioids, dissociatives, or 25x-NBOMe.

Chemische Struktur und Molekülprofil

α-PVP (1-phenyl-2-pyrrolidin-1-ylpentan-1-one) ist eine Referenzverbindung aus der Stoffklasse Cathinon-Derivate mit der Summenformel C15H21NO und einer molaren Masse von 231.33 g/mol. Die Stammverbindung wird unter der CAS-Nummer 14530-33-7 sowie in der NCBI-PubChem-Datenbank unter CID 11148955 geführt (Standard-InChIKey: YDIIDRWHPFMLGR-UHFFFAOYSA-N). Diese Verbindung teilt ihre Summenformel (C15H21NO) mit Konstitutions- oder Positionsisomeren; die eindeutige Identifizierung erfolgt über den vollständigen IUPAC-Namen und die CAS-Nummer (14530-33-7).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört α-PVP zur chemischen Klasse Cathinone, Substituted cathinones, Substituted pyrrolidines. Toxikologische Hinweise (PsychonautWiki): die genaue toxische Schwelle ist in der Fachliteratur nicht festgelegt. Abhängigkeitspotenzial (PsychonautWiki): hohes Potenzial für Toleranz- und Abhängigkeitsentwicklung. Dokumentierte Kreuztoleranz: dopamine, stimulant. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen

Dokumentierte Wechselwirkungen und Kontraindikationen

Hohes Risiko / Gefährliche Kombinationen

Unsichere Kombinationen (erhöhtes Risiko)

Ungeklärte Wechselwirkungen (Vorsicht geboten)